Drug General Information
Drug ID	D00JED
Former ID	DIB013295
Drug Name	AN-2898
Synonyms	PDE4 inhibitor (topical, psoriasis/atopic dermatitis), Anacor
Indication	Atopic dermatitis [ICD9: 691.8, 692.9; ICD10:L00-L99]		Phase 2	[523369]
Company	Anacor Pharmaceuticals Inc
Structure		Download 2D MOL 3D MOL
Canonical SMILES	c1(c(cc(cc1)Oc1cc2c(cc1)B(OC2)O)C#N)C#N
Target and Pathway
Target(s)	Type IV phosphodiesterase	Target Info	Inhibitor	[532329]
	CAMP-specific 3',5'-cyclic phosphodiesterase 4B	Target Info	Inhibitor	[532329]
	CAMP-specific 3',5'-cyclic phosphodiesterase 4A	Target Info	Inhibitor	[532329]
KEGG Pathway	Purine metabolism
	cAMP signaling pathway
	Morphine addictionhsa00230:Purine metabolism
	Morphine addiction
NetPath Pathway	IL5 Signaling Pathway
	IL2 Signaling Pathway
PathWhiz Pathway	Purine Metabolism
Reactome	DARPP-32 events
	G alpha (s) signalling eventsR-HSA-180024:DARPP-32 events
	G alpha (s) signalling events
WikiPathways	G Protein Signaling Pathways
	Myometrial Relaxation and Contraction Pathways
	TSH signaling pathwayWP35:G Protein Signaling Pathways
	Nuclear Receptors Meta-Pathway
	Opioid SignallingWP35:G Protein Signaling Pathways
References
Ref 523369	ClinicalTrials.gov (NCT01301508) Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis. U.S. National Institutes of Health.
Ref 532329	An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.